Roche Says Breast-Cancer Drug Shows Potential to Become Standard-Of-Care

Core Insights - Giredestrant has demonstrated a 30% reduction in the risk of disease recurrence or death when compared to standard-of-care endocrine therapy according to the company [1] Company Summary - Giredestrant is positioned as a significant advancement in treatment options, showing improved efficacy over traditional therapies [1]